TRIAL DATA
Phase 2 study combines pembrolizumab with chemotherapy in MSS CRC — Clinical Colorectal Cancer
A phase 2 study evaluated pembrolizumab (an immunotherapy) combined with capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient (MSS/pMMR) metastatic colorectal cancer. This combination approach aims to overcome the resistance to immunotherapy typically seen in MSS tumors.